Navigation Links
Cipla launches 3-in-1 AIDS drug in India

Cipla has launched an innovative combination of 3 HIV/AIDS drugs, Viraday that needs to be taken just once a day for effective treatment. //

The three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday, one tablet of which alone effectively treats a HIV infected person, eliminates the need for 3 separate medicines. This drug has some advantages like, it is less burdensome and it can be taken along with tuberculosis medicine, which could not be done previously.

This combination drug, that was previously available only in the U.S. and European countries, was first launched in India by Cipla on Thursday. In the U.S. and Europe this combination drug costs Rs. 52,800 a month, whereas Cipla will make it accessible at just Rs. 5,200 per month. This combination drug is less toxic than when the drugs are taken separately.

This breakthrough would improve the adherence-how faithfully patients stick to the course of treatment advised by the doctor. “This is a vital issue in HIV treatment to prevent the infection from reaching the advanced stage of AIDS,” said senior consultant in Internal Medicine at Indraprastha Apollo Hospital, Dr Nalin Nag. He said, “Viraday is very patient friendly, as it requires just one pill a day and freedom from the severe side effect of many other anti HIV drugs.”

The innovative treatment kits and the 3-in-1 pills introduced by Cipla will promote adherence and ease of use. Viraday is the most remarkable accomplishment of Cipla.

Cipla has brought down the price of HIV/AIDS drugs in international market. It supplies HIV/AIDS drugs to majority of African, South Asian, Latin American and several other developing countries.
YT
'"/>




Page: 1

Related medicine news :

1. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Cipla In India Can Manufacture Drug For Bird Flu
4. FDA Gives Preliminary Nod To Cipla And Sun Drugs
5. Ciplas HIV Drug Gets FDA Approval
6. Glaxo launches pills to help smokers quit in 7-12 weeks
7. Dr Reddy’s Laboratories launches Hyalosy
8. GlaxoSmithKline launches diabetes and cancer drugs
9. YSR launches Operation Dengue
10. Is Diabetes the Leading Cause of Kidney Failure in India
11. AIDS Disaster in India is Imminent
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular brushing ... achieve optimal results. This important necessity inspired an inventor from Las Vegas, Nev., to ... ensure that people break or avoid bad techniques of brushing the teeth in order ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine ... San Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in ... and beyond the standard of care, demonstrating leadership within the MPN community and/or a ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... highly innovative, personalized cell-based treatment for a high-risk form of the most ... Children,s Hospital of Philadelphia today reported new results ... The physician-scientists presented findings at the annual meeting of the ... Continue Reading ... ...
(Date:12/2/2016)... 2, 2016 bioLytical Laboratories, un líder mundial en test ... INSTI HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... Share, Development, Growth and Demand Forecast to 2022" report to their ... , , ... $6 billion in 2015, and it is expected to grow at a ... is expected to witness faster growth during the forecast period, a CAGR ...
Breaking Medicine Technology: